BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 34955325)

  • 1. Cost of human papillomavirus vaccine delivery in a single-age cohort, routine-based vaccination program in Senegal.
    Brennan T; Hidle A; Doshi RH; An Q; Loharikar A; Casey R; Badiane O; Ndiaye A; Diallo A; Loko Roka J; Mejia N; Abimbola T
    Vaccine; 2022 Mar; 40 Suppl 1(Suppl 1):A77-A84. PubMed ID: 34955325
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost of human papillomavirus vaccine delivery at district and health facility levels in Zimbabwe: A school-based vaccination program targeting multiple cohorts.
    Hidle A; Brennan T; Garon J; An Q; Loharikar A; Marembo J; Manangazira P; Mejia N; Abimbola T
    Vaccine; 2022 Mar; 40 Suppl 1(Suppl 1):A67-A76. PubMed ID: 35181152
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An evaluation of the cost of human papilloma virus (HPV) vaccine delivery in Zambia.
    Simuyemba MC; Chama-Chiliba CM; Chompolola A; Sinyangwe A; Bchir A; Asiimwe G; Chibwesha C; Masiye F
    BMC Infect Dis; 2024 Apr; 24(1):369. PubMed ID: 38565994
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A case study using the United Republic of Tanzania: costing nationwide HPV vaccine delivery using the WHO Cervical Cancer Prevention and Control Costing Tool.
    Hutubessy R; Levin A; Wang S; Morgan W; Ally M; John T; Broutet N
    BMC Med; 2012 Nov; 10():136. PubMed ID: 23146319
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost and operational context for national human papillomavirus (HPV) vaccine delivery in six low- and middle-income countries.
    Mvundura M; Slavkovsky R; Debellut F; Naddumba T; Bayeh A; Ndiaye C; Anena J; Vodicka E; Diop A; Gamage D; Musanabaganwa C; Tatkan G; Driwale A; Zelalem M; Badiane O; Ginige S; Hamilton E; Sibomana H; Lakew Y; Uwinkindi F; Dhufera A; Ampeire I; Kumar S; Lamontagne DS
    Vaccine; 2023 Nov; 41(49):7435-7443. PubMed ID: 37949752
    [TBL] [Abstract][Full Text] [Related]  

  • 6. National introduction of HPV vaccination in Senegal-Successes, challenges, and lessons learned.
    Casey RM; Adrien N; Badiane O; Diallo A; Loko Roka J; Brennan T; Doshi R; Garon J; Loharikar A
    Vaccine; 2022 Mar; 40 Suppl 1(Suppl 1):A10-A16. PubMed ID: 34593269
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Costs of delivering human papillomavirus vaccination to schoolgirls in Mwanza Region, Tanzania.
    Quentin W; Terris-Prestholt F; Changalucha J; Soteli S; Edmunds WJ; Hutubessy R; Ross DA; Kapiga S; Hayes R; Watson-Jones D
    BMC Med; 2012 Nov; 10():137. PubMed ID: 23148516
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Costs of delivering human papillomavirus vaccination using a one- or two-dose strategy in Tanzania.
    Hsiao A; Struckmann V; Stephani V; Mmbando D; Changalucha J; Baisley K; Levin A; Morgan W; Hutubessy R; Watson-Jones D; Whitworth H; Quentin W
    Vaccine; 2023 Jan; 41(2):372-379. PubMed ID: 36460537
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Experiences of operational costs of HPV vaccine delivery strategies in Gavi-supported demonstration projects.
    Botwright S; Holroyd T; Nanda S; Bloem P; Griffiths UK; Sidibe A; Hutubessy RCW
    PLoS One; 2017; 12(10):e0182663. PubMed ID: 29016596
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Costs of introducing and delivering HPV vaccines in low and lower middle income countries: inputs for GAVI policy on introduction grant support to countries.
    Levin A; Wang SA; Levin C; Tsu V; Hutubessy R
    PLoS One; 2014; 9(6):e101114. PubMed ID: 24968002
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Costs associated with delivering HPV vaccination in the context of the first year demonstration programme in southern Mozambique.
    Alonso S; Cambaco O; Maússe Y; Matsinhe G; Macete E; Menéndez C; Sicuri E; Sevene E; Munguambe K
    BMC Public Health; 2019 Aug; 19(1):1031. PubMed ID: 31370810
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A cost comparison of introducing and delivering pneumococcal, rotavirus and human papillomavirus vaccines in Rwanda.
    Ngabo F; Levin A; Wang SA; Gatera M; Rugambwa C; Kayonga C; Donnen P; Lepage P; Hutubessy R
    Vaccine; 2015 Dec; 33(51):7357-7363. PubMed ID: 26519548
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Health economic analysis of human papillomavirus vaccines in women of Chile: perspective of the health care payer using a Markov model.
    Gomez JA; Lepetic A; Demarteau N
    BMC Public Health; 2014 Nov; 14():1222. PubMed ID: 25424716
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness analysis of the introduction of the human papillomavirus vaccine in Honduras.
    Aguilar IB; Mendoza LO; García O; Díaz I; Figueroa J; Duarte RM; Perdomo G; Garcia AG; Janusz CB
    Vaccine; 2015 May; 33 Suppl 1():A167-73. PubMed ID: 25919157
    [TBL] [Abstract][Full Text] [Related]  

  • 15. National introduction of human papillomavirus (HPV) vaccine in Tanzania: Programmatic decision-making and implementation.
    Mphuru A; Li AJ; Kyesi F; Mwengee W; Mazige F; Nshunju R; Shayo B; Giattas MR; Loharikar A; Lyimo D
    Vaccine; 2022 Mar; 40 Suppl 1(Suppl 1):A2-A9. PubMed ID: 33962839
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost of a human papillomavirus vaccination project, Zimbabwe.
    Hidle A; Gwati G; Abimbola T; Pallas SW; Hyde T; Petu A; McFarland D; Manangazira P
    Bull World Health Organ; 2018 Dec; 96(12):834-842. PubMed ID: 30505031
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness of the introduction of two-dose bi-valent (Cervarix) and quadrivalent (Gardasil) HPV vaccination for adolescent girls in Bangladesh.
    Mahumud RA; Gow J; Alam K; Keramat SA; Hossain MG; Sultana M; Sarker AR; Islam SMS
    Vaccine; 2020 Jan; 38(2):165-172. PubMed ID: 31668820
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Feasibility and acceptability of nationwide HPV vaccine introduction in Senegal: Findings from community-level cross-sectional surveys, 2020.
    Doshi RH; Casey RM; Adrien N; Ndiaye A; Brennan T; Roka JL; Bathily A; Ndiaye C; Li A; Garon J; Badiane O; Diallo A; Loharikar A
    PLOS Glob Public Health; 2022; 2(4):e0000130. PubMed ID: 36962130
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Is expanding HPV vaccination programs to include school-aged boys likely to be value-for-money: a cost-utility analysis in a country with an existing school-girl program.
    Pearson AL; Kvizhinadze G; Wilson N; Smith M; Canfell K; Blakely T
    BMC Infect Dis; 2014 Jun; 14():351. PubMed ID: 24965837
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost of introducing and delivering RTS,S/AS01 malaria vaccine within the malaria vaccine implementation program.
    Baral R; Levin A; Odero C; Pecenka C; Tanko Bawa J; Antwi-Agyei KO; Amponsa-Achaino K; Chisema MN; Eddah Jalango R; Mkisi R; Gordon S; Morgan W; Muhib F
    Vaccine; 2023 Feb; 41(8):1496-1502. PubMed ID: 36710234
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.